The financials
ACADIA Pharmaceuticals Inc. by the numbers
ACADIA Pharmaceuticals Inc. (ACAD) reported revenue of $268M in Q1 2026 (quarter ended Mar 31, 2026), up 9.7% from the same quarter a year earlier. That came with a gross margin of 91% and net income of $3.6M (1.4% of revenue). For the full year FY2025, revenue was $1.07B (+12% year on year) and net income $391M. Its largest product in Jun 2026 was Nuplazid at $183M, 59% of the disclosed total, ahead of Daybue at 41%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $268M | $244M | +9.7% |
| Gross profit | $243M | $224M | +8.6% |
| Operating income | −$4.6M | $19M | to a loss |
| Net income | $3.6M | $19M | −81% |
| Diluted EPS | $0.02 | $0.11 | −82% |
| Product | Revenue | Share |
|---|---|---|
| Nuplazid | $183M | 59% |
| Daybue | $125M | 41% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $308.0M (+15%)
Daybue grew +30% year on yearNuplazid +8.7% year on year
Segment Latestquarter on quarteryear on year
- Nuplazid$183.1M$183.1MQoQ +9.7%year on year +8.7%+9.7%+8.7%
- Daybue$124.8M$124.8MQoQ +23%year on year +30%+23%+30%